By selectively inhibiting TYK2, deucravacitinib disrupts these cytokine-signaling pathways, effectively controlling keratinocyte hyperproliferation and inflammation in psoriasis [9,10]. The clinical efficacy of deucravacitinib has been demonstrated in two large phase III trials comparing it to both placebo and apremilast in patients with psoriasis [9]. Here, TYK2 is linked to psoriasis.